US 2023/0159655 A1Published application

Anti-cd73 antibody and use thereof

AssigneeAkeso Biopharma, Inc.

InventorsZhongmin WANG, Peng ZHANG, Baiyong LI, Yu XIA

Life of this patent

Estimating the term…

Abstract

Provided in the present invention are an anti-CD73 antibody and the use thereof. Specifically, a heavy chain variable region of the antibody contains HCDR1 to HCDR3 having amino acid sequences as shown in SEQ ID NOs: 15-17, respectively. Furthermore, a light chain variable region of the antibody contains LCDR1 to LCDR3 having amino acid sequences as shown in SEQ ID NOs: 18-20, respectively.

Claims16

Dependent claims

An anti-CD73 (for example, human CD73) antibody or an antigen-binding fragment thereof, wherein the anti-CD73 antibody comprises:

HCDR1, HCDR2 and HCDR3 contained in a heavy chain variable region set forth in SEQ ID NO:
2, SEQ ID NO:
6 or SEQ ID NO:
10;
and
LCDR1, LCDR2 and LCDR3 contained in a light chain variable region set forth in SEQ ID NO:
4, SEQ ID NO:
8, SEQ ID NO:
12 or SEQ ID NO:
14;
preferably, according to an IMGT numbering system,
the anti-CD73 antibody comprises:
HCDR1, comprising an amino acid sequence set forth in SEQ ID NO:
15, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence,
HCDR2, comprising an amino acid sequence set forth in SEQ ID NO:
16, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence,
HCDR3, comprising an amino acid sequence set forth in SEQ ID NO:
17, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence,
LCDR1, comprising an amino acid sequence set forth in SEQ ID NO:
18, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence,
LCDR2, comprising an amino acid sequence set forth in SEQ ID NO:
19, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence or an amino acid, or a sequence having one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence, and
LCDR3, comprising an amino acid sequence set forth in SEQ ID NO:
20, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence.

21 more elements

An isolated polypeptide, selected from the group consisting of:

(1) an isolated polypeptide, comprising sequences set forth in SEQ ID NO:
15, SEQ ID NO:
16 and SEQ ID NO:
17, wherein the polypeptide specifically binds to CD73 as a part of an anti-CD73 antibody, and the antibody further comprises sequences set forth in SEQ ID NO:
18, SEQ ID NO:
19 and SEQ ID NO:
20;
(2) an isolated polypeptide, comprising sequences set forth in SEQ ID NO:
18, SEQ ID NO:
19 and SEQ ID NO:
20, wherein the polypeptide specifically binds to CD73 as a part of an anti-CD73 antibody, and the antibody further comprises sequences set forth in SEQ ID NO:
15, SEQ ID NO:
16 and SEQ ID NO:
17;
(3) an isolated polypeptide, comprising a sequence set forth in SEQ ID NO:
2, SEQ ID NO:
6 or SEQ ID NO:
10, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence, wherein the polypeptide specifically binds to CD73 as a part of an anti-CD73 antibody, and the antibody further correspondingly comprises a sequence set forth in SEQ ID NO:
4, SEQ ID NO:
8 or SEQ ID NO:
12, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence;
(4) an isolated polypeptide, comprising a sequence set forth in SEQ ID NO:
4, SEQ ID NO:
8 or SEQ ID NO:
12, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence, wherein the polypeptide specifically binds to CD73 as a part of an anti-CD73 antibody, and the antibody further correspondingly comprises a sequence set forth in SEQ ID NO:
2, SEQ ID NO:
6 or SEQ ID NO:
10, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence;
(5) an isolated polypeptide, comprising a sequence set forth in SEQ ID NO:
10, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence, wherein the polypeptide specifically binds to CD73 as a part of an anti-CD73 antibody, and the antibody further correspondingly comprises a sequence set forth in SEQ ID NO:
14, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence;
and
(6) an isolated polypeptide, comprising the a sequence set forth in SEQ ID NO:
14, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence, wherein the polypeptide specifically binds to CD73 as a part of an anti-CD73 antibody, and the antibody further correspondingly comprises a sequence set forth in SEQ ID NO:
10, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence.

32 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/996,841Filed 22 Apr 2021
Priority: CN 202010324782.X22 Apr 2020
Published: 25 May 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/2896
Against receptors, cell surface antigens or cell surface determinants: against molecules with a "CD"-designation, not provided for elsewhere
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…
A61K 47/6871
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting an enzyme
A61P 35/00
Antineoplastic agents

Family

No related US applications are recorded in the indexed filing history.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

An anti-CD73 (for example, human CD73) antibody or an antigen-binding fragment thereof, wherein the anti-CD73 antibody comprises:

HCDR1, HCDR2 and HCDR3 contained in a heavy chain variable region set forth in SEQ ID NO:
2, SEQ ID NO:
6 or SEQ ID NO:
10;
and
LCDR1, LCDR2 and LCDR3 contained in a light chain variable region set forth in SEQ ID NO:
4, SEQ ID NO:
8, SEQ ID NO:
12 or SEQ ID NO:
14;
preferably, according to an IMGT numbering system,
the anti-CD73 antibody comprises:
HCDR1, comprising an amino acid sequence set forth in SEQ ID NO:
15, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence,
HCDR2, comprising an amino acid sequence set forth in SEQ ID NO:
16, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence,
HCDR3, comprising an amino acid sequence set forth in SEQ ID NO:
17, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence,
LCDR1, comprising an amino acid sequence set forth in SEQ ID NO:
18, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence,
LCDR2, comprising an amino acid sequence set forth in SEQ ID NO:
19, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence or an amino acid, or a sequence having one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence, and
LCDR3, comprising an amino acid sequence set forth in SEQ ID NO:
20, a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence, or an amino acid sequence having one or more (preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the sequence.

21 more elements

Facts

Application

17/996,841Filed 22 Apr 2021

Priority

CN 202010324782.X22 Apr 2020

Published

25 May 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/2896
Against receptors, cell surface antigens or cell surface determinants: against molecules with a "CD"-designation, not provided for elsewhere
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…
A61K 47/6871
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting an enzyme
A61P 35/00
Antineoplastic agents